ALLR Allarity Therapeutics, Inc.

NEUTRAL Impact: 2/10 S-3/A
Horizon weeks Filed Apr 24, 2026 Processed 1mo ago SEC 0001213900-26-047385
Shelf registration amendment
Latest settled — T+20d
ALLR ▲ +23.88% at T+20d
NEUTRAL call ✓ call won +23.88% · α vs SPY +19.85% · entry $1.34 → $1.66
Next anchor: T+60d in 5w
Last close $1.43 (close Jun 12) · +6.72% from $1.34 entry
Entry anchored
Apr 24, 12:43 PM ET
via Databento tick
T+1d
+2.24%
call +2.24% · α +2.07%
$1.37
settled 7w ago
T+5d
+0.75%
call +0.75% · α -0.16%
$1.35
settled 6w ago
T+20d
+23.88%
call +23.88% · α +19.85%
$1.66
settled 24d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

Allarity Therapeutics filed an amendment to its S-3 shelf registration to update the auditor consent, with no changes to the prospectus. The filing is administrative and does not disclose new offering terms, size, or pricing. This maintains the company's ability to issue securities on a delayed or continuous basis.

Actionable Insight

Monitor for future prospectus supplements or 8-K filings that may disclose actual offering terms, size, and use of proceeds. The current amendment is routine and does not trigger immediate trading implications.

Key Facts

  • Filing is an exhibits-only amendment to a previously filed S-3 shelf registration (File No. 333-293420).
  • Purpose is to update the auditor consent (Exhibit 23.2) from Wolf & Company, P.C.
  • No changes were made to the prospectus or offering details; no offering size, share count, or pricing disclosed.
  • Original S-3 was filed on February 12, 2026, and allows for future issuance of unspecified amounts of securities.

Financial Impact

No immediate financial impact — no capital raised in this filing. Potential for future dilution if shares are issued under the shelf.

dilutionmarket capshares outstanding

Risk Factors

  • Future ATM or follow-on offerings could lead to significant dilution given the small market cap ($22M).
  • Lack of disclosed offering terms increases uncertainty around timing and scale of potential capital raises.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
S-3/A Filing (Primary)0001213900-26-047385
Document: ea028739601ex23-2.htm0001213900-26-047385
Document: 0001213900-26-047385-index-headers.html0001213900-26-047385
Document: 0001213900-26-047385-index.html0001213900-26-047385
Document: 0001213900-26-047385.txt0001213900-26-047385
10 reports for ALLR
Performance horizon
100% Hit rate 5 of 5 directional calls best @ T+60▲ +38.71%Mar 6, 2026
Filters
Rows
Reports for ALLR — sortable, filterable
Type Now
May 11, 2026
4w ago
3
NEUTRAL ★ 1/10
$1.68 $1.43▼ −14.88%▼ −14.80%$1.43 (−14.88%)
May 8, 2026
5w ago
Press Release
NEUTRAL ★ 2/10
$1.55 $1.51▼ −2.58%▼ −4.04%$1.43 (−7.74%)
May 6, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$1.48 $1.52▲ +2.70%▲ +1.57%$1.43 (−3.38%)
Apr 27, 2026
6w ago
Press Release
BULLISH ★ 7/10
$1.37 $1.25▼ −8.76%▼ −9.16%$1.43 (+4.38%)
Apr 27, 2026
7w ago
EFFECT
NEUTRAL ★ 3/10
$1.37 $1.25▼ −8.76%▼ −9.16%$1.43 (+4.38%)
Apr 24, 2026
7w ago
S-3/A
NEUTRAL ★ 2/10
$1.34 $1.35▲ +0.75%▼ −0.16%$1.43 (+6.72%)
Apr 22, 2026
7w ago
8-K
BULLISH ★ 6/10
$1.40 $1.39▼ −0.81%▼ −0.87%$1.43 (+2.14%)
Apr 1, 2026
10w ago
8-K
BULLISH ★ 8/10
$1.13 $1.15▲ +1.77%▼ −2.00%$1.43 (+26.55%)
Mar 31, 2026
10w ago
Press Release
BULLISH ★ 7/10
$1.09 $1.16▲ +6.42%▲ +2.48%$1.43 (+31.19%)
Mar 6, 2026
14w ago
Press Release
BULLISH ★ 7/10
$1.24 $1.26▲ +1.61%▲ +3.14%$1.43 (+15.32%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 4h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access